BASKING RIDGE, N.J., April 11, 2014 /PRNewswire/ — Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $6.00 per share to the public. The gross proceeds to Regado from this offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Regado. The offering is expected to close on or about April 16, 2014, subject to the satisfaction of customary closing conditions. Regado has granted the underwriters a 30-day option to purchase up to an aggregate of 1,500,000 additional shares of common stock. Regado expects to use the net proceeds of this offering to fund further clinical development of its lead product candidate, REG1, and for working capital and other general corporate purposes.